In recent news, the trading of Guardant Health, Inc.’s (Nasdaq: GH) stock has been temporarily halted by Nasdaq. The U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee’s Molecular and Clinical Genetics Panel is set to meet today to review Guardant Health’s premarket approval (PMA) application for ShieldTM, a blood test designed to screen for colorectal cancer in average-risk adults. The panel meeting is scheduled to begin at 9:30 a.m. ET.
Guardant Health, founded in 2012, is a leading precision oncology company dedicated to revolutionizing patient care through its advanced blood and tissue tests, real-world data, and AI analytics. The company’s tests play a critical role in improving outcomes throughout all stages of care, from early cancer detection to recurrence monitoring in early-stage cancer and assisting doctors in choosing the most suitable treatment for patients with advanced cancer.
For more information about Guardant Health, visit their website at guardanthealth.com or follow them on LinkedIn, Twitter, and Facebook for updates and news. Investors can reach out to Zarak Khurshid at investors@guardanthealth.com while media inquiries can be directed to Mike Weist at press@guardanthealth.com or by calling +1 650-647-3643
